Terminal complement components play a role in the expression of C5a.
This study examined the expression of C5a detected antigenically (RIA) and functionally (PMN-myeloperoxidase release) consequent to classical or alternative pathway convertase cleavage. Maximal C5a expression occurred when C5 was cleaved in the presence of the later-acting complement components, C6, C7, and C8. This effect was detected by using both purified components and normal human serum immunochemically depleted of C7 or C8 and reconstituted with the purified component. C6 alone was not sufficient to augment C5a expression. Subsequent incubation of C6 and C7 with C5 cleaved in the absence of the terminal components was not sufficient for C5a release. Repeated freezing and thawing of C5 cleaved in the absence of C6 and C7 produced C5a equivalent to that detected when convertase cleavage occurred in the presence of the terminal components. Mild detergent treatment of convertase-cleaved C5 was not sufficient for C5a release. We believe that these data indicate a role for the terminal complement components in the expression of both C5a antigen and function. The mechanism for this effect is not known, but it may involve conformational changes in the C5 molecule that occur during membrane attack complex formation.
D003182:Complement C5 / Q000032:analysis / Q000276:immunology / Q000378:metabolism*; D015936:Complement C5a; D003183:Complement C6 / Q000502:physiology*; D003184:Complement C7 / Q000502:physiology*; D003185:Complement C8 / Q000502:physiology*; D015938:Complement Membrane Attack Complex; D003165:Complement System Proteins / Q000378:metabolism; D006461:Hemolysis; D006801:Humans
D003182:Complement C5; D003183:Complement C6; D003184:Complement C7; D003185:Complement C8; D015938:Complement Membrane Attack Complex; D015936:Complement C5a; D003165:Complement System Proteins